Vertex Pharmaceuticals OCI Cash Flow Hedge Gain (Loss), After Tax, Parent decreased by 117.4% to -$9.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 154.3%, from $17.30M to -$9.40M.
Fluctuations reflect the effectiveness of the company's hedging strategy and the underlying market volatility of the hedged items.
The net impact of cash flow hedging activities on comprehensive income after accounting for tax effects and reclassifica...
Standard reporting for companies utilizing derivative instruments to manage financial risk.
is_tmusz_oci_cash_flow_hedge_gain_loss_after_tax_parent| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $3.50M | $3.50M | $3.50M | $3.50M | -$3.20M | $17.30M | $54.10M | -$9.40M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -191.4% | +640.6% | +212.7% | -117.4% |
| YoY Change | — | — | — | — | -191.4% | +394.3% | >999% | -154.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.